Immunotherapy-Chemo cocktail tested for head and neck cancer – early trial stopped

NCT ID NCT02997332

Terminated Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (docetaxel, cisplatin, and 5-FU) is safe for people with advanced head and neck cancer. Only 14 patients were enrolled before the study was stopped. The goal was to find the right dose and check for serious side effects, but no final results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (immunotherapy) combined with docetaxel, cisplatin, and 5-fluorouracil (chemotherapy)
What this could lead to: If successful, this combination could improve outcomes for patients with advanced head and neck cancer by boosting the immune system's ability to fight tumors.
What could go wrong: This was a very early, small Phase 1 trial that was terminated, so results are limited. The added immunotherapy may increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCERS

Contacts and locations

Locations

Gustave Roussy

Villejuif, Val de Marne, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.